What information is available about cagrilintide, the investigational long‑acting amylin analogue for obesity and type‑2 diabetes?

Cagrilintide: An Investigational Long-Acting Amylin Analogue

Cagrilintide is a long-acting amylin receptor agonist currently in late-stage clinical development that demonstrates substantial weight loss (10-15%) and meaningful glycemic improvements when used alone or in combination with semaglutide (CagriSema) for treating obesity and type 2 diabetes. 1, 2

Mechanism of Action

Cagrilintide mimics the natural pancreatic hormone amylin, which:

• Induces satiety and promotes meal termination through central nervous system mechanisms
• Slows gastric emptying to reduce postprandial glucose excursions
• Suppresses prandial glucagon secretion
• Acts on heterodimeric amylin-calcitonin receptor complexes 3, 4

This represents a fundamentally different mechanism than GLP-1 receptor agonists, explaining the additive benefits when combined.

Clinical Efficacy Data

As Monotherapy

In the phase 2 dose-finding trial, cagrilintide demonstrated dose-dependent weight loss in adults with overweight/obesity without diabetes 5:

• Weight reduction ranged from 6.0% to 10.8% across doses (0.3-4.5 mg weekly)
• The 4.5 mg dose achieved 10.8% weight loss versus 3.0% with placebo at 26 weeks
• Superior to liraglutide 3.0 mg (10.8% vs 9.0%, p=0.03)

In Combination with Semaglutide (CagriSema)

The combination therapy shows synergistic rather than merely additive effects 2, 6:

REDEFINE 2 trial (Type 2 Diabetes + Obesity):

• Mean weight loss: -13.7% with CagriSema versus -3.4% with placebo at 68 weeks
• 73.5% achieved HbA1c ≤6.5% versus 15.9% with placebo
• Greater proportions achieved ≥5%, ≥10%, ≥15%, and ≥20% weight loss (all p<0.001) 2

REIMAGINE 2 trial (Type 2 Diabetes on Metformin ± SGLT2i):

• HbA1c reduction: -1.91% with CagriSema versus -1.75% with semaglutide alone
• Estimated treatment difference: -0.16% (95% CI -0.27 to -0.05, p=0.0035) 1

Phase 2 trial glycemic effects:

• HbA1c reduction: -2.2% with CagriSema versus -1.8% with semaglutide and -0.9% with cagrilintide
• Time in range (3.9-10.0 mmol/L) improved from 45.9% to 88.9% at 32 weeks 6

Meta-Analysis Findings

A systematic review pooling 5,023 participants confirmed 7:

• Cagrilintide: -6.08% weight loss (95% CI -8.02 to -4.14)
• CagriSema: -5.98% weight loss (95% CI -10.64 to -1.32)
• CagriSema produced significant reductions in waist circumference and HbA1c
• Cagrilintide alone showed modest blood pressure improvements

Safety Profile

Common Adverse Events

Gastrointestinal effects dominate the safety profile, similar to GLP-1 receptor agonists 1, 2, 5:

• Nausea: 20-47% across doses (versus 18% placebo)
• Constipation and diarrhea: 41-63% (versus 32% placebo)
• Most events are transient and mild-to-moderate in severity
• Tolerance typically develops during continued treatment

In REDEFINE 2, adverse events occurred in:

• 72.5% with CagriSema versus 34.4% with placebo
• Treatment discontinuation rates were comparable to placebo 2

Serious Considerations

• No level 2 or 3 hypoglycemia reported in trials 6
• No fatal adverse events in phase 2 studies 6, 5
• Overall adverse event rates were similar across treatment groups (68-80%) 6

Current Development Status

Cagrilintide is NOT yet FDA-approved but is in active phase 3 clinical development:

• Multiple ongoing trials: REIMAGINE 2, REDEFINE 2, and others
• Formulations under investigation: Weekly subcutaneous injection (2.4 mg dose most studied)
• Combination product (CagriSema): Co-formulated with semaglutide 2.4 mg for once-weekly injection 3

Clinical Context and Positioning

Comparison to Existing Therapies

While current guidelines recommend GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists (tirzepatide) as preferred agents for patients with type 2 diabetes and obesity 8, cagrilintide represents a novel mechanistic approach that:

• Complements rather than duplicates incretin-based mechanisms
• Achieves weight loss comparable to or exceeding current GLP-1 receptor agonists when used alone
• Demonstrates synergistic effects when combined with semaglutide, potentially offering superior outcomes to either agent alone

Potential Clinical Niche

Based on emerging evidence, cagrilintide-based therapies may be particularly valuable for 3, 4:

• Patients requiring greater weight loss than achievable with GLP-1 receptor agonists alone
• Those with inadequate response to incretin-based monotherapy
• Combination therapy approaches addressing obesity's biological complexity through multiple pathways

Important Caveats

The evidence base remains limited to clinical trials—real-world effectiveness, long-term safety beyond 68 weeks, and cardiovascular outcomes data are not yet available. Unlike established therapies such as liraglutide (LEADER trial) and semaglutide (SUSTAIN-6, FLOW trials) that have proven cardiovascular and renal benefits 8, cagrilintide lacks outcomes trial data demonstrating effects on morbidity and mortality.

Gastrointestinal tolerability requires careful patient counseling about eating smaller meals, adequate hydration, increased dietary fiber, eating slowly, and avoiding high-fat or spicy foods—the same strategies used for GLP-1 receptor agonist initiation 8.

This medication is investigational—it cannot currently be prescribed outside of clinical trials. Clinicians should monitor the literature for FDA approval decisions and subsequent guideline updates that will define its role in clinical practice.